What is the Treatment for Factor V Leiden ? Most people with Factor V Leiden do not form abnormal clots and require no treatment. If abnormal clots become an issue, "blood-thinning" medications, like Coumadin, can be used to impair the clotting system. This will halt growth of the clot and reduce the risk of future clots. Complications
The factor V Leiden mutation is the most common inherited risk factor for abnormal blood clotting in the United States. Factor V Leiden mutations are estimated to be carried by: 5% of Caucasians 2% of Hispanic Americans 1% Native Americans 1% African Americans 0.5% Asian Americans
The symptoms of Factor V deficiency vary in severity, even between members of the same family. In many cases, the symptoms of Factor V deficiency are so mild that they cause no problems. However, if the level of Factor V is low or absent or it does not work properly, symptoms may be present, often early in life.
ICD-10 code Z14. 8 for Genetic carrier of other disease is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
Acquired coagulation factor deficiency D68. 4 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM D68. 4 became effective on October 1, 2021.
Z83. 2 - Family history of diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | ICD-10-CM.
ICD-10 Code for Family history of carrier of genetic disease- Z84. 81- Codify by AAPC. Factors influencing health status and contact with health services. Persons with potential health hazards related to family and personal history and certain conditions influencing health status.
Factor V Leiden (FAK-tur five LIDE-n) is a mutation of one of the clotting factors in the blood. This mutation can increase your chance of developing abnormal blood clots, most commonly in your legs or lungs.
LOINC® Codes, Performing Laboratory If Factor V Leiden is Heterozygous for the R506Q mutation, then HR2 testing will be performed at an additional charge (CPT code: 81400).
This testing is considered investigational and is NOT a Medicare benefit.
In addition, a family history of blood clots can increase a person's risk. The chance of a blood clot increases when you have more risk factors.
NCD - Partial ThromboplastinTime (PTT) (190.16)
The PALB2 gene normally protects us from breast cancer. It contains instructions to make a protein that works with the Breast Cancer 1 and 2 (BRCA1 and BRCA2) genes to repair changes in the DNA code and prevent tumor growth. A gene is a piece of the DNA code that we inherit from our parents.
Mutations in the MUTYH gene cause an autosomal recessive form of familial adenomatous polyposis (also called MYH-associated polyposis). Mutations in this gene affect the ability of cells to correct errors made during DNA replication.
Mutations in the BRCA2 gene are associated with an increased risk of breast cancer in both men and women, as well as several other types of cancer. These mutations are present in every cell in the body and can be passed from one generation to the next.
The 2022 edition of ICD-10-CM Z14.8 became effective on October 1, 2021.
Categories Z00-Z99 are provided for occasions when circumstances other than a disease, injury or external cause classifiable to categories A00 -Y89 are recorded as 'diagnoses' or 'problems'. This can arise in two main ways:
Z77-Z99 Persons with potential health hazards related to family and personal history and certain conditions influencing health status
The 2022 edition of ICD-10-CM Z84.81 became effective on October 1, 2021.
Family history of diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism 1 Z83.2 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. 2 Short description: Family history of dis of the bld/bld-form org/immun mechnsm 3 The 2021 edition of ICD-10-CM Z83.2 became effective on October 1, 2020. 4 This is the American ICD-10-CM version of Z83.2 - other international versions of ICD-10 Z83.2 may differ.
The 2022 edition of ICD-10-CM Z83.2 became effective on October 1, 2021.
Z77-Z99 Persons with potential health hazards related to family and personal history and certain conditions influencing health status
Factor V Leiden is a mutation that is linked with thrombosis. The thrombosis is usually in the venous system. Examples include deep vein thrombosis and pulmonary embolism. A person can be homozygous or heterozygous to the factor V Leiden mutation. The risk is higher when both copies of the gene are defective compared to Factor V Leiden carriers.
What are the consequences of carrying the factor V Leiden mutation? Most people with factor V Leiden will not have a thrombotic event. In fact, only 1 of 10 will. Most people who had a clot do not have any identifiable mutation.
Factor V is part of the normal clotting mechanism. A defective factor V may lead to thrombosis or bleeding. The factor V Leiden mutation is relatively common and has been linked to thrombosis. This is a dominant mutation, but it is incomplete dominance. This means having the mutation does not automatically mean clots forming.
The literature points to the fact that heterozygous factor V Leiden carriers are at increased risk for clotting. However, this risk is not substantial in absolute numbers. Therefore it is not recommended that they be treated differently than others.
The mutation is inborn. It does not develop over life. The mechanism for thrombosis with factor V Leiden is as follows. Normal factor V is needed to propagate clot. It is usually deactivated by active protein C. Factor V Leiden will not be deactivated by activated protein C and will continue to propagate thrombosis.
In high risk situations it is still recommended that these patients receive VTE prophylaxis. This includes high risk surgery and the post-partum period (6 weeks). There is no recommendation to use prophylactic anticoagulation during pregnancy in asymptomatic carriers of factor V Leiden . Risk rises with age, but most pregnant women are young.